| **タイトル** | Metabolomics for Biomarker Discovery in Gastroenterological Cancer |
|-------------|---------------------------------------------------------------|
| **著者** | Nishiumi, Shin / Suzuki Makoto / Kobayashi, Takashi / Matsubara, Atsuki / Azuma, Takeshi / Yoshida, Masaru |
| **掲載誌・巻号・ページ** | Metabolites,4(3):547-571 |
| **刊行日** | 2014-07-07 |
| **資源タイプ** | Journal Article / 学術雑誌論文 |
| **版区分** | publisher |
| **権利** | ©2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
| **DOI** | 10.3390/metabo4030547 |
| **JaLCDOI** | |
| **URL** | http://www.lib.kobe-u.ac.jp/handle_kernel/90002773 |

PDF issue: 2018-11-04
Review

Metabolomics for Biomarker Discovery in Gastroenterological Cancer

Shin Nishiumi 1,*, Makoto Suzuki 1, Takashi Kobayashi 1, Atsuki Matsubara 1, Takeshi Azuma 1 and Masaru Yoshida 1,2,*

1 Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chu-o-ku, Kobe, Hyogo 650-0017, Japan; E-Mails: msuzuki@med.kobe-u.ac.jp (M.S.); kobatak@med.kobe-u.ac.jp (T.K.); amtbr@med.kobe-u.ac.jp (A.M.); azumat@med.kobe-u.ac.jp (T.A.)

2 Division of Metabolomics Research, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chu-o-ku, Kobe, Hyogo 650-0017, Japan

* Authors to whom correspondence should be addressed; E-Mails: nishiums@med.kobe-u.ac.jp (S.N.); myoshida@med.kobe-u.ac.jp (M.Y.); Tel.: +81-78-382-6305; Fax: +81-78-382-6309.

Received: 9 April 2014; in revised form: 11 June 2014 / Accepted: 25 June 2014 / Published: 7 July 2014

Abstract: The study of the omics cascade, which involves comprehensive investigations based on genomics, transcriptomics, proteomics, metabolomics, etc., has developed rapidly and now plays an important role in life science research. Among such analyses, metabolome analysis, in which the concentrations of low molecular weight metabolites are comprehensively analyzed, has rapidly developed along with improvements in analytical technology, and hence, has been applied to a variety of research fields including the clinical, cell biology, and plant/food science fields. The metabolome represents the endpoint of the omics cascade and is also the closest point in the cascade to the phenotype. Moreover, it is affected by variations in not only the expression but also the enzymatic activity of several proteins. Therefore, metabolome analysis can be a useful approach for finding effective diagnostic markers and examining unknown pathological conditions. The number of studies involving metabolome analysis has recently been increasing year-on-year. Here, we describe the findings of studies that used metabolome analysis to attempt to discover biomarker candidates for gastroenterological cancer and discuss metabolome analysis-based disease diagnosis.
1. Introduction to Metabolomics

1.1. Omics

The study of the omics cascade, which involves comprehensive investigations based on genomics, transcriptomics, proteomics, metabolomics, etc., has developed rapidly and now plays an important role in life science research. Genomics makes it possible to find gene mutations and gene polymorphisms, and there is an abundance of reports about genomics-based studies. Transcriptomics is an approach in which biological samples are analyzed to obtain information about the concentrations of a large number of mRNA transcripts in a simultaneous manner. The latter information includes gene expression data related to functional genomics. Recently, the comprehensive analysis of microRNA molecules has attracted increasing attention in the life science field, especially the medical research field. In proteomics, information about protein expression levels and functions, such as about abnormal protein expression, protein phosphorylation, and protein interactions, is evaluated, and a great number of academic papers about such research have been published. Recently, metabolomics or metabolome analysis, which involves the comprehensive analysis of low molecular weight metabolites, has rapidly developed along with improvements in analytical technology leading to its use in a variety of research fields including clinical, cell biology, and plant/food science studies [1–4].

1.2. Characteristics of Metabolomics

Metabolome analysis is used to evaluate the characteristics and interactions of low molecular weight metabolites under a specific set of conditions, for example, at a particular developmental stage, in certain environmental conditions, or after specific genetic modifications. The metabolome mainly represents the endpoint of the omics cascade and is also the closest point in the cascade to the phenotype. Changes in metabolite levels can also be induced by exogenous factors, such as environmental and dietary factors, while genomic information is not basically affected by such factors. Moreover, in addition to expression variations, the metabolome is also affected by the enzymatic activities of various proteins. Therefore, metabolite profiles are considered to be a summary of the other upstream omics profiles, and metabolome analysis might be able to detect subtle changes in metabolic pathways and deviations from homeostasis before phenotypic changes occur [5,6]. Taken together, the metabolite profile of a cell is more likely to represent the cell’s status than its DNA, RNA, or protein profile. On the basis of these facts, metabolomics has started to be used in medical research. In such studies, metabolomics has mainly been utilized to discover biomarker candidates for cancer. For example, a search of the papers included in the PubMed database [7] using the keywords “metabolomics”, “cancer”, and “biomarker” found a total of 377 papers, and the number has been increasing year-on-year. In addition, metabolomics can also be used to examine unknown pathological conditions. Here, we describe the findings of studies that have used metabolome analysis to attempt to
discover biomarker candidates for gastroenterological cancer and discuss metabolome analysis-based disease diagnosis.

2. Metabolism in Cancer

D. Hanahan and R.A. Weinberg suggested that the following characteristics are hallmarks of cancer: sustained proliferation, evasion from growth suppressors, active invasion and metastasis, the enabling of replicative immortality, the induction of angiogenesis, resistance to cell death, the deregulation of cellular energetics, avoidance of immune destruction, tumor-promoting inflammation, and genome instability and mutation [8,9]. Among these characteristics, the deregulation of cellular energetics seems to be particularly related to metabolomics research. Actually, in the study by Hirayama et al., metabolome analysis using capillary electrophoresis-mass spectrometry (CE-MS) demonstrated that colon and gastric tumors produce energy by glycolysis rather than oxidative phosphorylation via the tricarboxylic acid cycle, even in the presence of an adequate oxygen supply, which is known as “the Warburg effect” [10]. The accumulation of significantly higher levels of most amino acids, which are indirectly used as energy sources, in tumor tissue compared with non-tumor tissue has also been reported [10]. In addition, cancer cells obtain energy via glutaminolysis as well as glycolysis [11]. The relationship between “active and metastasis” and metabolites has started to be elucidated. Sarcosine, which is an N-methyl derivative of the amino acid glycine, was identified as a potentially important metabolic intermediary for prostate cancer cell invasion and aggressivity [12]. It was also proposed that glycine metabolism may represent a metabolic vulnerability in rapidly proliferating cancer cells [13]. Thus, metabolites themselves seem to affect cancer cells somehow, and these findings suggest that the pathogenesis of cancer leads to alterations in metabolite levels in the body. If such metabolite alterations influence the metabolite levels in biological fluids such as serum/plasma, urine, and saliva, it may be possible to use the metabolite concentrations of such fluids as biomarkers of cancer.

3. Biomarker Discovery in Gastroenterological Cancer Using Metabolomics

3.1. Biomarker Discovery and Gastroenterological Cancer

Gastroenterological cancer is a group of cancers including esophageal, gastric, colorectal, hepatic, and pancreatic cancer. Oral cancer may be also included in gastroenterological cancer. Gastroenterological cancer remains relatively asymptomatic until it reaches the progressive state, at which point it exhibits poor prognosis. Therefore, methods that facilitate the detection of gastroenterological cancer at an earlier stage are desired, because early stage cancer patients are highly likely to make a complete recovery from such conditions. Regarding gastroenterological cancer, biomarkers that make it possible to accurately predict prognosis, therapeutic efficacy, and adverse effects are also required. Recently, studies on metabolomics-based biomarker discoveries have been widely reported (Table 1). In addition, there are some articles in which the metabolite alterations in tumor tissues were evaluated using tissue metabolome analysis and the results leading to elucidation of pathogenesis of gastroenterological cancer were shown (Table 1). The pathogenesis of gastroenterological cancer is considered to be closely associated with lifestyle factors as well as genome mutations associated with
oncogenes and tumor suppressor genes. Therefore, metabolomics is likely to be a suitable method for biomarker discovery [14], as described in the “Introduction to Metabolomics”.

3.2. Metabolomics-Based Biomarker Discovery

Metabolomics-based biomarker discovery studies for gastroenterological cancer have been widely performed by liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), CE-MS, nuclear magnetic resonance (NMR) spectroscopy or Fourier transform-infrared (FT-IR) spectroscopy (Table 1). MS-based techniques exhibit relatively high selectivity and sensitivity during such analyses, and therefore, they have often been used for metabolite profiling. In metabolite profiling, analyses have been performed focusing on the metabolites related to the specific pathways, e.g., amino acids, organic acids, carbohydrates, and lipids [15], and then precise identification of the metabolites and correction for analytical inaccuracies are needed [16]. On the contrary, metabolic fingerprinting is the method for sample classification, and the target samples’ spectral patterns based on their biological state and/or origin are available [17]. NMR and FT-IR spectroscopy display relatively low selectivity so they are often used in metabolite fingerprinting aimed at evaluating the differences among biological samples, although there have been some studies in which metabolite profiling was performed using NMR and FT-IR. Therefore, metabolite profiling and metabolite fingerprinting are applied to metabolomics-based biomarker discovery.

3.3. Biomarker Discovery in Gastroenterological Cancer by Metabolomics

Previous studies about metabolome analysis in patients with gastroenterological cancer have analyzed the metabolites present in serum/plasma, saliva, urine, feces, and/or tissue samples, and there is a particular abundance of reports about the metabolites found in serum/plasma samples. Recent reports about metabolome analysis in patients with gastroenterological cancer are listed in Table 1. Metabolome analysis-based attempts to elucidate biomarker candidates for gastroenterological cancer have been carried out using a variety of techniques including GC-MS, LC-MS, CE-MS, NMR, and Fourier transform ion cyclotron resonance (FTICR)-MS. Each approach has different characteristics, and it is impossible to measure all metabolites including hydrophobic and hydrophilic molecules using a single technique. Therefore, in some biomarker discovery studies, a variety of instruments were used, which allowed the researchers to evaluate the potential of a wide range of metabolites as novel biomarkers. However, there were some inconsistencies between the results obtained by different research groups. For example, in the report by Chen et al. the urine level of isoleucine was higher in colorectal cancer patients compared with healthy controls [18]. On the contrary, Qiu et al. demonstrated that colorectal cancer patients had lower urinary levels of isoleucine [19]. In addition, differences between the presence and absence of significant alterations in metabolite concentrations have also been observed. These discrepancies might have been due to the differences in the methods used to collect the biological samples, and these issues are discussed in Section 4. Thus, although there is an abundance of reports about the use of metabolome analysis to discover biomarker candidates for gastroenterological cancer, no firm conclusions have yet been reached.
Table 1. A list of recent reports in which patients with gastroenterological cancer were subjected to metabolome analysis.

| Disease               | Specimen      | Upregulated Metabolites                           | Downregulated Metabolites | Analytical Method   | Ref. |
|-----------------------|---------------|--------------------------------------------------|---------------------------|---------------------|------|
| Oral cancer           | Saliva        | Lactate; α-Eicosanoate                            | Valine; GABA; Phenylalanine | UPLC-Q-TOF/MS       | [20] |
| **Research aim:**     |               | To discover salivary metabolite biomarkers and to explore salivary metabolomics as a disease diagnostic tool |                           |                     |      |
| Oral cancer           | Saliva        | Cadaverine; 2-Aminobutyrate; Alanine; Piperidine; Taurine; Piperide; Pipocolate; Pyrroline hydroxycarboxylate; Betaine; Leucine + Isoleucine; Phenylalanine; Tyrosine; Histidine; Valine; Tryptophan; β-Alanine; Glutamate; Threonine; Serine; Glutamine; Choline; Carnitine | None                     | CE-TOF-MS       | [21] |
| **Research aim:**     |               | To predict oral cancer susceptibility via saliva-based diagnostics based on metabolomics technology |                           |                     |      |
| Oral cancer           | Urine         | Alanine; Valine; Serine; Tyrosine; Cystine 6-Hydroxynicotinate; Hippurate |                           | GC-QMS                 | [22] |
| **Research aim:**     |               | To establish a diagnostic tool for early stage oral squamous cell carcinoma and its differentiation from other oral conditions by the urinary metabolite profiling approach |                           |                     |      |
| Oral cancer           | Serum         | Glycerate; Serine; Laurate; N-Acetyl-L-aspartate; Asparagine; Ornithine; Heptadecanate | None                     | GC-QMS                 | [23] |
| **Research aim:**     |               | To find metabolite biomarker candidates for detection of early stage oral squamous cell carcinoma |                           |                     |      |
| Esophageal cancer     | Mucosal tissue| L-Valine; Naphthalene; 1-Butanamine; Pyrimidin; Aminoquinoline; L-Tyrosine; Isoleucine; Purine; Serine; Phosphate; myo-Inositol; Arabinofuranose; L-Asparagine; Tetradecanoate; 1-Alanine; Hexadecanoate | L-Altrose; D-Galactofuranoside; Arabinose; Bisethane | GC-QMS                 | [24] |
| **Research aim:**     |               | To find tissue metabolomic biomarkers that are identifiable and diagnostically useful for esophageal cancer |                           |                     |      |
Table 1. Cont.

| Disease           | Specimen | Upregulated Metabolites                                                                 | Downregulated Metabolites                                                                 | Analytical Method | Ref. |
|-------------------|----------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|------|
| Esophageal cancer | Mucosal tissue | N-acetylaspartate; Glutamate; Valine; Leucine + Isoleucine; Tyrosine; Methionine; Phenylalanine; GABA; Phenylacetylglutamine; Glutamic acid γ-H; Unsaturated lipids; Short-chain fatty acids; Phosphocholine; Glycopolysaccharides; Acetone; Malonate; Acetoacetate; Acetate; Trimethylamine; Formate; Uracil; Adenine in ATP/ADP and NAD/NADH; Acetyl hydrazine; Hippurate | Creatine; Glycine; Glutamine; 4-Hydroxyphenylpyruvate; Creatinine; Taurine; Aspartate; myo-Inositol; Cholesterol; Choline; Glucose; Ethanol; α-Ketoglutarate oxime; AMP; NAD | NMR              | [25] |
| Esophageal cancer | Tissue   | Choline; Alanine; Glutamate | Creatinine; myo-Inositol; Taurine | NMR              | [26] |
| Esophageal cancer | Urine    | Urea; Acetate; Pantethein; 3-Hydroxyisovalerate; Acetone; Formate; 2-Hydroxyisobutyrate; Creatinine; Ethanolamine; 2-Aminobutyrate; Leucine; Succinate; Glutamine; Glucose; Glycine; Tryptophan; Trimethylamine-N-oxide; Valine; Lactate; Tyrosine | Dimethylamine; Alanine; Citrate | NMR              | [27] |
| Esophageal cancer | Serum    | Uridine | 1-Methyladenosine; N2,N2-Dimethylguanosine; N2-Methylguanosine; Cytidine | LC-QqQ/MS | [28] |
| Esophageal cancer | Serum    | Lactate; β-Hydroxybutyrate; Lysine; Glutamine; Citrate | Valine; Leucine + Isoleucine; Methionine; Tyrosine; Tryptophan; Myristate; Linoleate | LC-Q-TOF/MS NMR | [29] |

Research aim: To find the potential tissue metabolite biomarkers for clinical diagnosis for different stages of human esophageal cancer and new insights for the mechanism research

Research aim: To establish the biochemical profiles of adjacent non-involved tissue and malignant esophageal tumor and to determine the metabolomic changes of tumors with different tumor differentiation for finding metabolomic indicators sensitive to tumor differentiation

Research aim: To find urinary metabolite signatures that can clearly distinguish both Barrett’s esophagus and esophageal cancer from controls

Research aim: To investigate whether nucleosides can potentially serve as useful biomarkers to identify esophageal adenocarcinoma
| Disease        | Specimen | Upregulated Metabolites                                                                 | Downregulated Metabolites                                                                 | Analytical Method | Ref. |
|---------------|----------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------|------|
| Esophageal cancer | Serum    | β-Hydroxybutyrate; Acetoacetate; Creatine; Creatinine; Lactate; Glutamate; Glutamine; Histine | LDL/VLDL; Unsaturated lipids; Acetate; α-Glucose; β-Glucose; Tyrosine                      | NMR              | [30] |
| Research aim: | To identify the metabolite based biomarkers associated with the early stages of esophageal adenocarcinoma with the goal of improving prognostication |
| Esophageal cancer | Serum    | Lactate; Glycolate; Malonate; Fumarate; L-Serine; L-Aspartate; L-Glutamine              | Pyruvate                                                                                 | GC-QMS           | [31] |
| Research aim: | To characterize the systemic metabolic disturbances underlying esophageal cancer and to identify possible early biomarkers for clinical prognosis |
| Esophageal cancer | Plasma   | Phosphatidylinositol; Lithocholytaurine; Phosphatidate; L-Urobinigen; 9'-Carboxy-γ-tocotrienol; PC; PE; Sphinganine 1-phosphate; Phosphatidylyserine(16:0/14:0); LPC(22:2); Ganglioside GM2(d18:1/24:1(15Z)); Lithocholate 3-O-glucuronide; 12-Oxo-20-dihydroxy-leukotriene B4 | Desmosine; Isodesmosine; 5-β-Cyprinol sulfate | UPLC-TOF/MS      | [32] |
| Research aim: | To investigate the differences in serum metabolite profiles using a metabolomic approach and to search for sensitive and specific metabolomic biomarker candidates |
| Gastric cancer | Tissue   | 2-Aminobutyrate; 3-Aminoisobutanoate; Valine; 2-Hydroxy-4-methyl-pentanoate; Isoleucine; Proline; Uracil; Threonine; Thymine; Dihydrouracil; Aspartate; Pyroglutamate; GABA; Cysteine; Glutamate; Dodecanoate; Asparagine; Putrescine; Cadaverine; Ascorbate; Gluconate; Xanthine; N-Acetyl glucosamine; Kynurenine; Inosine | Hydroxyacetate; 3,4-Dihydroxy-2(3H)-furanone; Nicotinamide; Glycerol phosphate; Tetradecanoate; Palmitelaidate; Palmitate; Linoleate; Stearate; Arachidonate; l-Palmitoyl-glycerol; Sucrose; Cholesterol | GC-TOF/MS        | [33] |
**Table 1. Cont.**

| Disease       | Specimen     | Upregulated Metabolites                                                                 | Downregulated Metabolites                                      | Analytical Method | Ref. |
|---------------|--------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------|-------------------|------|
| **Research aim:** To reveal the major metabolic alterations essential for the development of gastric cardia cancer and to discover a biomarker signature of gastric cardia cancer |
| Gastric cancer | Urine        | Arginine; Leucine; Valine; Isoleucine; Lactate                                           | Methionine; Serine; Aspartate; Histidine; Succinate; Citrate; Malate | CE-MS             | [34] |
| **Research aim:** To search for potential tumor markers of gastric cancer in patients’ urine samples |
| Gastric cancer | Serum        | 3-Hydroxypropionate; 3-Hydroxyisobutyrate                                               | Pyruvate; Octanoate; Phosphate                                  | GC-QMS            | [31] |
| **Research aim:** To investigate the differences in serum metabolite profiles using a metabolomic approach and to search for sensitive and specific metabolomic biomarker candidates |
| Gastric cancer | Serum        | L-Valine; Sarcosine; Hexadecanenitrile                                                   | L-Glutamine; Hexanedioate; 9,12-Octadecadienoate; 9-Octadecenoate; trans-13-Octadecenoate; Nonahexacontanoate; Cholesta-3,5-diene; Cholesterol/Pentafluoropropionate; Cholesterol; Cholest-5-en-3-ol; Fumarate; 2-O-Mesyl arabinose; Benzeneacetonitrile; 2-Amino-4-hydroxypteridinone; 1,2,4-Benzencarboxylate | GC-QMS            | [35] |
| **Research aim:** To explore the underlying metabolic mechanisms of gastric cancer and to identify biomarkers associated with morbidity |
| Colorectal cancer | Mucosal tissue | Lactate; Phosphate; L-Glycine; 2-Hydroxy-3-methylvalerate; L-Proline; L-Phenylalanine; Palmitate; Margarate; Oleate; Stearate; Uridine; 11,14-Eicosadienoate; 11-Eicosanoate; 1-O-Heptadecylglycerol; 1-Monooleoylglycerol; Propyl octadecanoate; Cholesterol | Fumarate; Malate; D-Mannose; D-Galactose; D-Glucose; 1-Hexadecanol; Arachidonate | NMR GC-QMS        | [36] |

**Research aim:** To reveal that global metabolic profiling of colon mucosae can define metabolic signatures for not only discriminating malignant from normal mucosae but also distinguishing the anatomical and clinicopathological characteristics of colorectal cancer
Table 1. Cont.

| Disease          | Specimen | Upregulated Metabolites                                                                 | Downregulated Metabolites                                                  | Analytical Method          | Ref.  |
|------------------|----------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------|-------|
| Colorectal cancer| Tissue   | Glycine; L-Proline; L-Phenylalanine; L-Alanine; L-Leucine; L-Valine; L-Serine; L-Threonine; L-Isoleucine; Picolinate; L-Methionine; L-Aspartate; β-Alanine; Aminomalonate; 1-Methylhydantoin; Palmitate; Margarate; Oleate; Stearate; 11-Eicosenoate; Myristate; Pentadecanoate; Linolenate; Lignocerate; Phosphate; 1-L-Arabinose; Lactate; Maleate; Pantothenate; Glycerol; 1-Monooleoylglycerol; Uracil; Uridine; Cholesterol | Arachidonate; D-Mannose; D-Galactose; D-Glucose; Fumarate; Malate; Oxalate; Succinate; Ribitol; Squalene | GC×GC-TOF/MS | [37]  |
| Colorectal cancer| Urine    | Lactate; Arginine; Leucine; Isoleucine; Valine                                                                                           | Histidine; Methionine; Aspartate; Serine; Succinate; Citrate; Malate       | CE-IT/MS                   | [18]  |
| Colorectal cancer| Urine    | 5-Hydroxytryptophan; 5-Hydroxyindoleacetaet; Tryptophan; Glutamate; Pyroglutamate; N-Acetyl-aspartate; p-Cresol; 2-Hydroxyhippurate; Phenylacacetate; Phenylacetylglutamine; p-Hydroxyphenylacacetate | Succinate; Isocitrate; Citrate; 3-Methylhistidine; Histidine               | GC-QMS                     | [19]  |
| Colorectal cancer| Serum    | None                                                                                                                                  | FAs (C_{28}H_{46}O_{4}, C_{28}H_{48}O_{4}, C_{28}H_{50}O_{4})               | FTICR-MS                   | [38]  |

**Research aim:** To investigate whether the metabotype associated with colorectal cancer is distinct from that of normal tissue and whether various biochemical processes are altered by pathogenesis of colorectal cancer.

**Research aim:** To investigate the metabolic profile of urine metabolites and to elucidate their clinical significance in patients with colorectal cancer including possibility as the biomarker candidates for early detection.

**Research aim:** To demonstrate the potentials of this noninvasive urinary metabolomic strategy as a complementary diagnostic tool for colorectal cancer.

**Research aim:** To discover putative metabolomic markers associated with colorectal cancer.
| Disease          | Specimen | Upregulated Metabolites                                                                 | Downregulated Metabolites                                      | Analytical Method | Ref. |
|------------------|----------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------|------|
| Colorectal cancer| Serum    | Pyruvate; α-Hydroxybutyurate; Phosphate; Isoleucine; β-Alanine; meso-Erythritol; Aspartate; Pyroglutamate; Glutamate; ρ-Hydroxybenzoate; Arabinose; Asparagine; Xylitol; Ornithine; Citrulline; Glucuronate; Glucosamine; Palmitoleate; Inositol; Kynurenine; Cystamine; Cystine; Lactitol | Nonanoate; Creatinine; Ribulose; O-Phosphoethanolamine          | GC-QMS            | [39] |
|                   |          | Research aim: To establish new screening methods for early diagnosis of colorectal cancer via metabolomics |
| Colorectal cancer | Serum    | Lactate; Glycolate; L-Alanine; 3-Hydroxypropionate; L-Proline; L-Methionine; Thioglycolate; L-Glutamate; L-Asparagine; L-Glutamine; Glucuronic lactone | None                                                           | GC-QMS            | [31] |
|                   |          | Research aim: To investigate the differences in serum metabolite profiles using a metabolomic approach and to search for sensitive and specific metabolomic biomarker candidates |
| Colorectal cancer | Serum    | LPC(16:0); LPC(18:2); LPC(18:1); LPC(18:0); LPC(20:4); LPC(22:6); PC(34:1); LPA(16:0); LPA(18:0); LPC(16:0) | Palmitic amide; Oleamide; Hexadecanedioate; Octadecanoate; Eicosatrienoate; Myristate | DI-FTICR-MS       | [40] |
|                   |          | Research aim: To discriminate colorectal cancer patients from controls by metabolobolic biomarkers and to reveal the stage-related biomarkers for colorectal cancer and the changing trends of four lipid species in the colorectal cancer progression |
| Hepatic cancer    | Tissue   | Arachidyl carnitine; Tetradecanal; Oleamide                                            | β-Sitosterol; L-Phenylalanine; LPC(18:2); Glycerophosphocholine; LPE(18:3); Chenodeoxycholate glycine conjugate; LPC(22:6); Quinaldate; LPE(18:0); LPC(18:0); LPC(20:4) | LC-LTQ-Orbitrap-MS | [41] |
|                   |          | Research aim: To select characteristic endogenous metabolites in hepatitis B virus-related hepatocellular carcinoma patients and to identify their molecular mechanism and potential clinical value |
### Table 1. Cont.

| Disease         | Specimen | Upregulated Metabolites                                                                 | Downregulated Metabolites                                                                 | Analytical Method | Ref. |
|-----------------|----------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|------|
| Hepatic cancer  | Urine    | Octanedioate; Glycine; Tyrosine; Threonine; Butanedioate                                 | Heptanedioate; Ethanedioate; Xylitol; Urea; Phosphate; Propanoate; Pyrimidine; Butanoate; Trihydroxypentanoate; Hypoxanthine; Arabinofuranose; Hydroxyproline dipeptide; Xylonate | GC-QMS            | [42] |
| Hepatic cancer  | Serum    | Cortisol; GCA; GCDCA; C16:1-CN; FAs (C16:1, C16:0, C18:2, C18:1, C18:0, C20:5, C20:4, C20:2, C22:6, C22:5) | Tryptophan; LPC(14:0); LPC(20:3); LPC(20:5); C10-CN; C10:1-CN; C8-CN; C6-CN              | LC-Q-TOF/MS       | [43] |
| Hepatic cancer  | Plasma   | LPC(24:0); Glycodeoxycholate; Deoxycholate 3-sulfate                                   | LPC(14:0); LPC(16:0); LPC(18:0); LPC(18:1); LPC(18:2); LPC(18:3); LPC(20:4); FA(24:0); FA(24:1); LPC(20:2); LPC(20:3); LPC(20:5) | UPLC-QqQ/MS       | [44] |
| Hepatic cancer  | Feces    | LPC(18:0); LPC(16:0)                                                                   | Chenodeoxycholate dimeride; Urobiolin; Urobilinogen; 7-Ketolithocholate                  | UPLC-Q-TOF/MS     | [45] |
| Pancreatic cancer | Saliva | Cadaverine; 2-Aminobutyrate; Alanine; Putrescine; Methylimidazole acetate; Trimethylamine; Piperidine; Leucine + Isoleucine; Phenylalanine; Tyrosine; Histidine; Proline; Lysine; Glycine; Ornithine; Burimamide; Ethanolamine; GABA; Aspartate; Valine; Tryptophan; β-Alanine; Glutamate; Threonine; Serine; Glutamine; Hypoxanthine; Choline; Carnitine | Taurine; Glycerophosphocholine                                                           | CE-TOF-MS         | [21] |

**Research aim:**
- To investigate the urinary metabolic difference between hepatocellular carcinoma patients and normal subjects and to find biomarkers for hepatocellular carcinoma.
- To study the related metabolic deregulations in hepatocellular carcinoma and chronic liver diseases and to discover the differential metabolites for distinguishing the different liver diseases.
- To evaluate the molecular changes in the plasma of hepatocellular carcinoma patients and to provide new insights into the pathobiology of the diseases.
- To find fecal metabolite biomarkers for distinguishing liver cirrhosis and hepatocellular carcinoma patients from healthy controls.
Table 1. Cont.

| Disease      | Specimen | Upregulated Metabolites                                                                 | Downregulated Metabolites                                                                 | Analytical Method | Ref. |
|--------------|----------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|------|
| Research aim: |          | To reveal the comprehensive salivary metabolic profiles of pancreatic cancer patients and healthy controls and to identify cancer-specific biomarkers with high discriminative ability |                                                                                          | UPLC-TOF/MS       | [46] |
| Pancreatic cancer | Tissue  | Taurine                                                                                | Succinate; Malate; Uridine; Glutathione; UDP-N-Acetyl-D-glucosamine; NAD; UMP; AMP       |                   |      |
| Research aim: |          | To investigate the differences in the metabolite profiles of normal and pancreas tumor tissue with a goal of developing prognostic biomarkers |                                                                                          | GC-QMS            | [47] |
| Pancreatic cancer | Serum   | Lactate; Thiodiglycolate; 7-Hydroxyoctanoate; Asparagine; Aconitate; Homogentisate; N-Acetyl-tyrosine | Glycine; Urea; Octanoate; Glycerate; Decanoate; Laurate; Myristate; Palmitate; Urate; Margarate; Stearate |                   |      |
| Research aim: |          | To evaluate the differences in the metabolomes between pancreatic cancer patients and healthy volunteers and to aid the discovery of novel biomarkers |                                                                                          | GC-QMS            | [48] |
| Pancreatic cancer | Serum   | Arabinose; Ribulose                                                                     | Valine; 2-Aminoethanol; n-Caprylate; Threonine; Nonanoate; Methionine; Creatinine; Asparagine; Glutamine; O-Phosphoethanolamine; Glycyglycine; 1,5-Anhydro-D-glucitol; Lysine; Histidine; Tyrosine; Urate |                   |      |
| Research aim: |          | To construct a diagnostic model for pancreatic cancer using serum metabolomics and to confirm its diagnostic performance |                                                                                          | GC-TOF/MS         | [49] |
| Pancreatic cancer | Plasma  | Arachidonate; Erythritol; Cholesterol; N-Methylalanine; Lysine; Deoxycholylglycine; Cholylglycine; LPC(16:0); Taurosodeoxycholate; Taurocholate; LPC(18:2); PE(26:0); PC(34:2) | Glutamine; Hydrocinnamate; Phenylalanine; Tryptamine; Inosine |                   |      |
| Research aim: |          | To seek novel metabolic biomarkers of pancreatic cancer                                  |                                                                                          |                   |      |

In this review, we searched for the articles, in which the evaluations of differences between cancer and control were performed by metabolomics using gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), capillary electrophoresis-mass spectrometry (CE-MS), Fourier transform ion cyclotron resonance (FTICR-MS) and nuclear magnetic resonance (NMR), via PubMed database and so on, and their articles were shown in Table 1. In Table 1, the instruments used for metabolomics were described to specify the analytical method, and the aim of each article was also stated. In Table 1, upregulated or downregulated metabolites in serum/plasma, saliva, feces or urine of the cancer patients compared with healthy controls were listed. Regarding tissues, upregulated or
downregulated metabolites in tumor tissues compared with non-tumor (normal) tissues in cancer patients were shown. Table 1 shows the list of metabolites that were demonstrated to be significantly changed between cancer and control in each article. In some articles, many metabolites with the significant alterations between cancer and control were exerted. Regarding these articles, only metabolites that were determined as biomarker candidates based on each criterion was listed in Table 1. Abbreviations: GABA, \( \gamma \)-Aminobutyrate; LPC, Lysophosphatidylcholine; PC, Phosphatidylcholine; LPA, Lysophosphatidate; LPE, Lysophosphatidylethanolamine; PE, Phosphatidylethanolamine; FA, Fatty acids; GCDCA, Glycochenodeoxycholate; GCA, Glycocholate; UDP, Uridine diphosphate; NAD, Nicotinamide adenine dinucleotide; UMP, Uridine monophosphate; AMP, Adenosine monophosphate; ATP, Adenosine triphosphate; CE-IT/MS, Capillary electrophoresis-ion-trap/mass spectrometry; CE-MS, Capillary electrophoresis-mass spectrometry; CE-TOF-MS, Capillary electrophoresis-time-of-flight mass spectrometry; DI-FTICR-MS, Direct infusion-Fourier transform ion cyclotron resonance-mass spectrometry; FTICR-MS, Fourier transform ion cyclotron resonance-mass spectrometry; GC×GC-TOF/MS, Two-dimensional gas chromatography-time-of-flight mass spectrometry; GC-QMS, Gas chromatography-quadrupole mass spectrometry; GC-TOF/MS, Gas chromatography-time-of-flight mass spectrometry; LC-IT/MS, Liquid chromatography-ion-trap/mass spectrometry; LC-LTQ-Orbitrap-MS, Liquid chromatography-linear ion trap quadrupole-Orbitrap-mass spectrometry; LC-QqQ/MS, Liquid chromatography-quadrupole/mass spectrometry; LC-Q-QqQ/MS, Liquid chromatography-quadrupole-time-of-flight/mass spectrometry; NMR, nuclear magnetic resonance; QqQ-MS, Triple quadrupole-mass spectrometry; UPLC-QqQ/MS, Ultra performance liquid chromatography-triple quadrupole/mass spectrometry; UPLC-Q-TOF/MS, Ultra performance liquid chromatography-quadrupole-time-of-flight/mass spectrometry; UPLC-TOF/MS, Ultra performance liquid chromatography-time-of-flight/mass spectrometry.
3.4. Early Stage Cancer and Metabolomics

Early detection of cancer is very important for a complete recovery. Therefore, many researchers have searched for possible biomarkers of early cancer detection. In biomarker discovery research using metabolomics, evaluations of early cancer detection have been carried out. In the study by Kobayashi et al., a diagnostic model for pancreatic cancer was established using GC-MS-based serum metabolomics and multiple logistic regression analysis accompanied by the stepwise method [48]. This established model had a high sensitivity of 77.8% in resectable pancreatic cancer, namely relatively early stage pancreatic cancer, while sensitivities of CA19-9 and CEA were 55.6% and 44.4%, respectively. In serum lipid analysis for colorectal cancer, the metabolite profile data based on palmitic amide, oleamide, hexadecanedioate, octadecanoate acid, eicosatrienoate, LPC(18:2), LPC(20:4), LPC(22:6), myristate and LPC(16:0) exerted a sensitivity of 0.981 in early stage colorectal cancer patients compared to healthy volunteers [40]. In the analysis of plasma amino acids, alterations in levels of amino acids were observed in early stage lung, gastric, colorectal, breast, and prostate cancer [50]. Thus, the metabolites in biological fluids seem to be changed at the early stage of cancers, and metabolomics may be a powerful strategy for biomarker discovery, although detailed validation is still lacking at this point in time.

3.5. The Relationship between Metabolite Alterations and Cancer

Recently, studies aimed at biomarker candidate discovery based on amino acid-specific metabolite profiling have also been performed [50]. Moreover, it was demonstrated that high-mobility group box 1 protein (HMGB1) is released during the development and progression of colorectal cancer and subsequently induces muscle tissues to supply glutamine to cancer cells [51]. These findings suggest that increased HMGB1 levels lead to alterations in the blood amino acid profile and increased glutamine levels in colorectal tumors. In the paper by Miyagi et al. [50], the plasma level of tryptophan was significantly decreased in five types of cancer, i.e. lung, gastric, colorectal, breast and prostate cancer compared with healthy controls. Tryptophan is converted to kynurenine by indoleamine-2,3-dioxygenase, and it has been demonstrated that indoleamine-2,3-dioxygenase is over-expressed in cancer cells [52]. The possibility that indoleamine-2,3-dioxygenase may cause immune escape of various different tumors [52–55] has also been suggested, and that over-expression of indoleamine-2,3-dioxygenase in tumors may increase tryptophan metabolism, leading to a decreased of tryptophan in cancer patients. In addition, as shown in Table 1, the level of lactate seems to be upregulated in various gastroenterological cancers. Lactate is synthesized from pyruvate in the anaerobic condition, and it is known that this lactate synthesis is upregulated in cancer cells. This phenomenon is called “the Warburg effect” [56], so this reaction possibly promotes lactate synthesis, leading to an increased level of lactate. Thus, it seems that there are not only specific metabolite alterations in certain cancers but also common metabolite alterations in various cancers. These metabolite alterations are more likely to be reflected by the results of the metabolite biomarker candidates. Therefore, to draw firm conclusions about metabolite biomarker candidates for gastroenterological cancer it is important to understand the relationship between metabolite alterations and cancer, and moreover to elucidate the reasons for the observed alterations in the metabolite profile.
4. Future of Metabolomics-Based Disease Diagnosis

4.1. Procedures for Long-Term and Large-Scale Metabolomics Research

In the future, metabolomics is expected to be used in the clinical setting to screen for a variety of diseases including gastroenterological cancers. If metabolomics technology in screening programs enables early diagnosis, it can result in marked improvements in patients’ quality of life. Recently, the Human Serum Metabolome (HUSERMET) Consortium recommended the procedures for long-term and large-scale metabolomic studies involving thousands of human serum/plasma samples [57]. Subsequently, a method for the global metabolite profiling of animal and human tissues has also been proposed [58]. The HUSERMET Consortium recommended the methods for sample collection, sample preparation, and data acquisition for LC-MS- and GC-MS-based studies and also pointed out that the most important stage in large-scale metabolomic studies is appropriate sample collection, because the systematic failure at the beginning of the investigation could invalidate the whole study. In addition, they proposed the protocols for large-scale GC-MS-based metabolomic studies, which describe the number of samples that should be prepared each week and the number of samples that should be measured in a day and recommend the usage of the retention index instead of retention time. The use of standard operating procedures based on validated protocols is important for studies attempting to find novel metabolite biomarker candidates. Quality control and assurance (QC/QA) is also important in the long-term and large-scale metabolomic studies [57,59–62]. Samples for QC are analyzed every batch throughout all measurement batches, and signal intensity, peak shape, retention time, separation resolution, mass accuracy, and the amount of detectable peaks are checked by using data obtained from QC samples. The pooled biological fluid samples and standard compound mixture samples may be used as QC samples. Before starting the batch measurement, it may be required to confirm the status of the injector, the mass spectrometer, and so on. Instrument tuning including mass calibration and sensitivity check is also required routinely as well as after the instrument maintenance. Recently, the analyzing workflow for the large-scale non-targeted serum metabolite profiling by LC-MS was visualized in a PubMed-indexed video journal [63].

4.2. Sampling for Biomarker Discovery Research by Metabolomics

In the clinical setting, the analyses of biomarkers present in serum/plasma, saliva, urine, and tissue samples have been prevalent. However, collecting tissues is invasive, and therefore serum/plasma, saliva, and urine are well used. Especially serum/plasma biomarkers are preferable due to the ease of collection, and there are a variety of biomarker studies using serum/plasma. In the metabolomics research field, serum/plasma are also well used, and metabolomics-based studies evaluating the differences between plasma and serum metabolite levels have been carried out recently. In the report by Yu et al. [64], the serum levels of 104 of 122 metabolites were found to be about 10% higher than their plasma levels, and nine metabolites displayed serum levels that were more than 20% higher than their plasma levels. Yu et al. demonstrated that both plasma and serum metabolite data exhibited good reproducibility, but the plasma data displayed better reproducibility than the serum data. In another report by Yin et al. [65], it was stated that the exposure of blood to room temperature led to increased levels of hypoxanthine and sphingosine 1-phosphate, and hence, Yin et al. suggested that the following
procedures should be employed during sample collection: the use of ethylenediaminetetraacetic acid (EDTA)-plasma samples is recommended for situations involving the metabolomic analysis of clinical samples; hemolyzed samples should be excluded; blood should be placed in ice water immediately after collection and should not be stored for longer than 2 h; the use of non-refrozen plasma is recommended (repeated freezing should not be performed), and MS data should be carefully examined for unexpected signals (the selection of blood collection tubes is also important because chemical noise derived from blood collection tubes can interfere with data analysis). In addition, the intra- and/or inter-day variance of metabolite levels has to be taken into consideration. Intra- and/or inter-day variance data has been reported for some metabolites [39,66,67]; for example, a previous study found that the tryptophan levels observed in the afternoon and at night were significantly lower than those detected in the morning. During pre-treatment and the subsequent measurement process, some metabolites might be unstable, and thus, it is necessary to confirm their corresponding metabolites and to eliminate any unstable metabolites from the subsequent analyses.

As for urine, the need to correct the obtained metabolite concentrations is an issue, although the correction using creatine and creatinine levels has been described in a great number of studies. However, collecting urine is non-invasive, and urine requires less sample pretreatment, because the protein level in urine is lower leading to a lack of complexity. Thus, urine has a number of advantages as an analytical material over other biological fluids [68–70], and in the future it may be recognized that urine is the most suitable biological fluids for the metabolomic approach to obtain meaningful diagnostic information.

Recently, metabolomic studies using saliva have also been carried out in the medical research field [20,21]. In humans, there are the three paired major salivary glands—the parotid gland, the submandibular gland, and the sublingual gland—and saliva is secreted from these major salivary glands. Saliva contains various DNAs, mRNAs, proteins including enzymes and antibodies, metabolites, and other molecules. Some of these molecules pass into the saliva from the blood stream via transcellular or paracellular routes. Therefore, saliva may correspond to blood regarding the reflection the physiological state of the body, and may be useful as a material containing disease biomarkers. Saliva collection is easy and noninvasive, and moreover, no specialized equipment is needed to obtain saliva [71]. Now, salivary diagnostics is recognized as one of the main approaches in biomedical basic and clinical areas [72], and it has been demonstrated that molecules in saliva may be associated with disease conditions [73–75]. To date, the number of metabolomics studies using saliva is small, but the potential of saliva metabolomics as a biomarker discovery approach has been proven by the accumulated results from saliva metabolomics.

4.3. Validation for Biomarker Discovery Research by Metabolomics

After discovering novel metabolite biomarker candidates whilst paying careful attention to the above issues, validation testing should be performed. In the disease biomarker discovery research, the use of samples obtained from other facilities is also important. The proposal by Yin et al. as shown above [65], lists considerable issues when the validation research is carried out in other facilities. In addition, during validation, it might be better to use different instruments from those utilized to detect novel metabolite biomarker candidates. Furthermore, techniques other than MS should be employed.
When MS is used, it is necessary to prepare stable isotopes corresponding to the metabolite biomarker candidates if possible. The quantitative performance of mass spectrometers is affected by various factors such as ion suppression [76]. Therefore, stable isotopes are required to obtain detailed quantitative information about alterations in the levels of the target molecules [77]. Stable isotopes will also be essential for quantitative evaluations if the metabolomics-based research using MS is to result in practical clinical applications. During the validation process and in clinical practice, the use of multiple reaction monitoring (MRM) coupled with stable isotopes and triple quadrupole (QqQ) MS is a powerful method for measuring the levels of targeted metabolites, because MRM based on QqQ-MS leads to molecule detection with high sensitivity, selectivity, reproducibility as well as a broad dynamic analysis range. MRM coupled with stable isotope dilution using QqQ-MS is a longtime and principal method to quantify small molecules and also a powerful method for quantitative measurement of targeted proteins [78–80] Recently, an analysis of mouse blood metabolites using GC/QqQ-MS was validated, although the study did not use stable isotopes [81]. An metabolomic article describes the quantification of metabolites in serum/plasma carried out by LC-MS coupled with stable isotopes as internal standards, which are contained in the AbsoluteIDQTM p180 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria) [82]. Through a strict validation process, the candidates can be narrowed down to several metabolites, and some biomarker candidates that exhibit high repeatability can be utilized for clinical application after assay optimization.

### 4.4. Assay Optimization of Mass Spectrometry-Based Metabolomics

Regarding the assay optimization of MS-based analysis systems, some problems remain to be resolved, for example, it would be useful if the following processes could be automated: (1) metabolite extraction; (2) the pre-treatment process; (3) data analysis including peak alignment, annotation, and identification; and (4) the output of the obtained results. Regarding the automation of metabolite extraction and the pre-treatment process, dried blood spot sampling, in which blood is blotted and dried on filter paper, and supercritical fluid extraction (SFE), which is an extraction technique involving the use of supercritical carbon dioxide, have been studied. When SFE is performed, it is not necessary to perform sample pre-treatment, and SFE is also suitable for extracting hydrophobic compounds. Recently, SFE was combined with MS, and the analysis of blood metabolites using this system accompanied by dried plasma spotting is currently being investigated [83]. Then, in biomarker research, the analysis of volatile organic compounds (VOCs), which include molecules such as alcohols, aldehydes, ketones, and other heterocyclic compounds, has been performed with combination of headspace-solid phase microextraction (HS-SPME) and GC-MS [84–86]. In this combination approach, the solvent extraction step for volatile analysis is not needed. Moreover, the analyzing system for VOCs in blood was constracted using in-tube extraction (ITEX), which is superior to HS-SPME [87]. The systems using HS-SPME and ITEX do not need manual metabolite extraction from biological fluids, and so this may be useful for assay optimization. In addition, some studies have used an automated system for sample preparation before MS measurement [88,89]. Although the study regarding the automation of each process is ongoing, at present the metabolites are manually extracted via liquid-liquid and solid-phase extraction, and other processes are also largely performed manually.
4.5. Mass Spectrometry Data Preprocessing, Peak Alignment and Peak Identification

For automatic MS data preprocessing, peak alignment, and molecule identification, software for metabolome analysis are freely available or can be purchased. Examples of the software include MetAlign, XCMS, MZmine, Aloutput, and MRMPROBS [90–94]. For metabolite identification in metabolome analysis, the metabolite database including mass spectrum and retention time/retention time index may be used. Construction of an in-house database is needed, but METLIN and MassBank are also available for metabolite peak identification based on the fragment ion data [95]. To obtain the metabolite information such as the biological/biochemical characteristics and the related pathway, the Human Metabolome Database (HMDB), Kyoto Encyclopedia of Genes and Genomes (KEGG), Recon X and so on are convenient [96–98]. Especially, HMDB includes spectral data for human metabolites.

Thus, the technology for metabolome analysis is being innovated, the information is accumulated, resulting in development of the metabolomics-based biomarker discovery research. However, easier extraction, pretreatment, and data analysis methods are required to make metabolome analysis more practical. Therefore, it is hoped that an automated analysis system that performs all of the required processes from metabolite extraction to data output will be developed.

5. Conclusions

The Japanese population has the highest life expectancy in the world. Due to its aging society, the working population in Japan has been rapidly decreasing, and now the most populous age group is the 60-69-year-olds. As a result, the medical costs of elderly people in Japan have increased every year, and these increases are regarded as a financial problem for the national government. Therefore, the development of a low-cost and easy diagnostic approach for detecting diseases at an early stage is needed to reduce medical expenses. Similar problems have arisen in various developed countries. Recently, various types of clinical samples have been subjected to metabolome analysis using GC-MS, LC-MS, CE-MS, matrix-assisted laser desorption ionization (MALDI)-MS, NMR spectrometry, or FT-IR spectrometry in order to discover novel biomarkers and elucidate the onset mechanisms of diseases. It is important to obtain disease-specific metabolome profiles in order to increase our understandings of diseases. Novel findings based on these disease-specific metabolome profiles are useful not only for discovering new biomarkers and elucidating the onset mechanisms of diseases, but also for developing novel therapeutic strategies, although accomplishing these aims will probably require the integration of omics data obtained from genomics-, transcriptomics-, and proteomics-based approaches as well as data acquired using metabolomics. The metabolomics-based research will hopefully increase our understanding of various diseases and lead to the elucidation of novel metabolite biomarkers. In addition, the development of metabolomics-based screening processes that only require a single drop of blood and allow diseases to be diagnosed at an early stage is greatly desired.

Acknowledgments

This study was supported, in part, by a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [M.Y.], a Grant-in-Aid for Challenging Exploratory Research from the Ministry of Education, Culture, Sports, Science, and
Technology of Japan [M.Y.], and a grant from the Development of Systems and Technology for Advanced Measurement and Analysis Project (JST) [S.N, M.S., M.Y.], a grant of the National Center for Global Health and Medicine 25–104, Ministry of Health, Labor, and Welfare of Japan [M.Y.], and Special Coordination Funds for Promoting Science and Technology, Creation of Innovation Centers for Advanced Interdisciplinary Research Areas (Innovative Bioproduction Kobe), the Ministry of Education, Culture, Sports, Science, and Technology of Japan [T.A., M.Y.]

Author Contributions

Shin Nishiumi planned and wrote the manuscript. Makoto Suzuki, Takashi Kobayashi, Atsuki Matsubara, Takeshi Azuma and Masaru Yoshida commented on and modified the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Spratlin, J.L.; Serkova, N.J.; Eckhardt, S.G. Clinical applications of metabolomics in oncology: A review. *Clin. Cancer Res.* **2009**, *15*, 431–440.
2. Mashego, M.R.; Rumbold, K.; de Mey, M.; Vandamme, E.; Soetaert, W.; Heijnen, J.J. Microbial metabolomics: Past, present and future methodologies. *Biotechnol. Lett.* **2007**, *29*, 1–16.
3. Wishart, D.S. Metabolomics: Applications to food science and nutrition research. *Trends Food Sci. Technol.* **2008**, *19*, 482–493.
4. Saito, K. Phytochemical genomics—A new trend. *Curr. Opin. Plant Biol.* **2013**, *16*, 373–380.
5. Nambiar, P.R.; Gupta, R.R.; Misra, V. An “Omics” based survey of human colon cancer. *Mutat. Res.* **2010**, *693*, 3–18.
6. Rochfort, S. Metabolomics reviewed: A new “Omics” platform technology for systems biology and implications for natural products research. *J. Nat. Prod.* **2005**, *68*, 1813–1820.
7. PubMed. Available online: http://www.ncbi.nlm.nih.gov/pubmed (accessed on 11 June 2014).
8. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. *Cell* **2000**, *100*, 57–70.
9. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674.
10. Hirayama, A.; Kami, K.; Sugimoto, M.; Sugawara, M.; Toki, N.; Onozuka, H.; Kinoshita, T.; Saito, N.; Ochiai, A.; Tomita, M.; et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. *Cancer Res.* **2009**, *69*, 4918–4925.
11. Dang, C.V. Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells? *Cell Cycle* **2010**, *9*, 3884–3886.
12. Sreekumar, A.; Poisson, L.M.; Rajendiran, T.M.; Khan, A.P; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R.J.; Li, Y.; et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature* **2009**, *457*, 910–914.
13. Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A.L.; Kafri, R.; Kirschner, M.W.; Clish, C.B.; Mootha, V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. *Science* 2012, 336, 1040–1044.

14. Yoshida, M.; Hatano, N.; Nishiumi, S.; Irino, Y.; Izumi, Y.; Takenawa, T.; Azuma, T. Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry. *J. Gastroenterol.* 2012, 47, 9–20.

15. Niwa, T. Metabolic profiling with gas chromatography-mass spectrometry and its application to clinical medicine. *J. Chromatogr.* 1986, 379, 313–345.

16. Oldiges, M.; Lütz, S.; Pflug, S.; Schroer, K.; Stein, N.; Wiendahl, C. Metabolomics: Current state and evolving methodologies and tools. *Appl. Microbiol. Biotechnol.* 2007, 76, 495–511.

17. Fiehn, O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. *Comp. Funct. Genomics* 2001, 2, 155–168.

18. Chen, J.L.; Fan, J.; Yan, L.S.; Guo, H.Q.; Xiong, J.J.; Ren, Y.; Hu, J.D. Urine Metabolite Profiling of Human Colorectal Cancer by Capillary Electrophoresis Mass Spectrometry Based on MRB. *Gastroenterol. Res. Pract.* 2012, 2012, 125890.

19. Qiu, Y.; Cai, G.; Su, M.; Chen, T.; Liu, Y.; Xu, Y.; Ni, Y.; Zhao, A.; Cai, S.; Xu, L.X.; *et al.* Urinary metabonomic study on colorectal cancer. *J. Proteome Res.* 2010, 9, 1627–1634.

20. Wei, J.; Xie, G.; Zhou, Z.; Shi, P.; Qiu, Y.; Zheng, X.; Chen, T.; Su, M.; Zhao, A.; Jia, W. Salivary metabolite signatures of oral cancer and leukoplakia. *Int. J. Cancer* 2011, 129, 2207–2217.

21. Sugimoto, M.; Wong, D.T.; Hirayama, A.; Soga, T.; Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. *Metabolomics* 2010, 6, 78–95.

22. Xie, G.X.; Chen, T.L.; Qiu, Y.P.; Shi, P.; Zheng, X.J.; Su, M.M.; Zhao, A.H.; Zhou, Z.T.; Jia, W. Urine metabolite profiling offers potential early diagnosis of oral cancer. *Metabolomics* 2012, 8, 220–231.

23. Kimoto, A.; Nishiumi, S.; Kobayashi, T.; Terashima, Y.; Suzuki, H.; Takeuchi, J.; Azuma, T.; Komori, T.; Yoshida, M. A novel gas chromatography mass spectrometry-based serum screening method for oral squamous cell carcinoma. *Head Neck Oncol.* 2013, 5, 40.

24. Wu, H.; Xue, R.; Lu, C.; Deng, C.; Liu, T.; Zeng, H.; Wang, Q.; Shen, X. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2009, 877, 3111–3117.

25. Wang, L.; Chen, J.; Chen, L.; Deng, P.; Bu, Q.; Xiang, P.; Li, M.; Lu, W.; Xu, Y.; Lin, H.; *et al.* \(^1\)H-NMR based metabonomic profiling of human esophageal cancer tissue. *Mol. Cancer* 2013, 12, doi:10.1186/1476-4598-12-25.

26. Yang, Y.; Wang, L.; Wang, S.; Liang, S.; Chen, A.; Tang, H.; Chen, L.; Deng, F. Study of metabonomic profiles of human esophageal carcinoma by use of high-resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis. *Anal. Bioanal. Chem.* 2013, 405, 3381–3389.

27. Davis, V.W.; Schiller, D.E.; Eurich, D.; Sawyer, M.B. Urinary metabolomic signature of esophageal cancer and Barrett’s esophagus. *World J. Surg. Oncol.* 2012, 10, doi:10.1186/1477-7819-10-271.
28. Djukovic, D.; Baniasadi, H.R.; Kc, R.; Hammoud, Z.; Raftery, D. Targeted serum metabolite profiling of nucleosides in esophageal adenocarcinoma. *Rapid Commun. Mass Spectrom.* 2010, 24, 3057–3062.

29. Zhang, J.; Bowers, J.; Liu, L.; Wei, S.; Gowda, G.A.; Hammoud, Z.; Raftery, D. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. *PLoS One* 2012, 7, e30181.

30. Zhang, X.; Xu, L.; Shen, J.; Cao, B.; Cheng, T.; Zhao, T.; Liu, X.; Zhang, H. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. *Biochim. Biophys. Acta* 2013, 1832, 1207–1216.

31. Ikeda, A.; Nishiumi, S.; Shinohara, M.; Yoshie, T.; Hatano, N.; Okuno, T.; Bamba, T.; Fukusaki, E.; Takenawa, T.; Azuma, T.; *et al.* Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. *Biomed. Chromatogr.* 2012, 26, 548–558.

32. Liu, R.; Peng, Y.; Li, X.; Wang, Y.; Pan, E.; Guo, W.; Pu, Y.; Yin, L. Identification of Plasma Metabolomic Profiling for Diagnosis of Esophageal Squamous-Cell Carcinoma Using an UPLC/TOF/MS Platform. *Int. J. Mol. Sci.* 2013, 14, 8899–8911.

33. Cai, Z.; Zhao, J.S.; Li, J.J.; Peng, D.N.; Wang, X.Y.; Chen, T.L.; Qiu, Y.P.; Chen, P.P.; Li, W.J.; Xu, L.Y.; *et al.* A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. *Mol. Cell. Proteomics* 2010, 9, 2617–2628.

34. Chen, J.L.; Fan, J.; Lu, X. CE-MS based on moving reaction boundary method for urinary metabolomic analysis of gastric cancer patients. *Electrophoresis* 2014, 35, 1032–1039.

35. Song, H.; Peng, J.S.; Dong-Sheng, Y.; Yang, Z.L.; Liu, H.L.; Zeng, Y.K.; Shi, X.P.; Lu, B.Y. Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. *Braz. J. Med. Biol. Res.* 2012, 45, 78–85.

36. Chan, E.C.; Koh, P.K.; Mal, M.; Cheah, P.Y.; Eu, K.W.; Backshall, A.; Cavill, R.; Nicholson, J.K.; Keun, H.C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). *J. Proteome Res.* 2009, 8, 352–361.

37. Mal, M.; Koh, P.K.; Cheah, P.Y.; Chan, E.C. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. *Anal. Bioanal. Chem.* 2012, 403, 483–493.

38. Ritchie, S.A.; Ahiahonu, P.W.; Jayasinghe, D.; Heath, D.; Liu, J.; Lu, Y.; Jin, W.; Kavianpour, A.; Yamazaki, Y.; Khan, A.M.; *et al.* Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: Implications for early screening and detection. *BMC Med.* 2010, 8, doi:10.1186/1741-7015-8-13.

39. Nishiumi, S.; Kobayashi, T.; Ikeda, A.; Yoshie, T.; Kibi, M.; Izumi, Y.; Okuno, T.; Hayashi, N.; Kawano, S.; Takenawa, T.; *et al.* A novel serum metabolomics-based diagnostic approach for colorectal cancer. *PLoS One* 2012, 7, e40459.

40. Li, F.; Qin, X.; Chen, H.; Qiu, L.; Guo, Y.; Liu, H.; Chen, G.; Song, G.; Wang, X.; Li, F.; *et al.* Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. *Rapid Commun. Mass Spectrom.* 2013, 27, 24–34.
41. Liu, S.Y.; Zhang, R.L.; Kang, H.; Fan, Z.J.; Du, Z. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. *World J. Gastroenterol.* **2013**, *19*, 3423–3432.

42. Wu, H.; Xue, R.; Dong, L.; Liu T.; Deng, C.; Zeng, H.; Shen, X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. *Anal. Chim. Acta* **2009**, *648*, 98–104.

43. Zhou, L.; Wang, Q.; Yin, P.; Xing, W.; Wu, Z.; Chen, S.; Lu, X.; Zhang, Y.; Lin, X.; Xu, G. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. *Anal. Bioanal. Chem.* **2012**, *403*, 203–213.

44. Patterson, A.D.; Maurhofer, O.; Beyoglu, D.; Lanz, C.; Krausz, K.W.; Pabst, T.; Gonzalez, F.J.; Dufour, J.F.; Idle, J.R. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. *Cancer Res.* **2011**, *71*, 6590–6600.

45. Cao, H.; Huang, H.; Xu, W.; Chen, D.; Yu, J.; Li, J.; Li, L. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. *Anal. Chim. Acta* **2011**, *691*, 68–75.

46. Kaur, P.; Sheikh, K.; Kirilyuk, A.; Kirilyuk, K.; Singh, R.; Ressom, H.W.; Cheema, A.K. Metabolomic profiling for biomarker discovery in pancreatic cancer. *Int. J. Mass Spectrom.* **2012**, *310*, 44–51.

47. Nishiumi, S.; Shinohara, M.; Ikeda, A.; Yoshie, T.; Hatano, N.; Kakuyama, S.; Mizuno, S.; Sanuki, T.; Kutsumi, H.; Fukusaki, E.; et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. *Metabolomics* **2010**, *6*, 518–528.

48. Kobayashi, T.; Nishiumi, S.; Ikeda, A.; Yoshie, T.; Sakai, A.; Matsubara, A.; Izumi, Y.; Tsumura, H.; Tsuda, M.; Nishisaki, H.; et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. *Cancer Epidemiol. Biomark. Prev.* **2013**, *22*, 571–579.

49. Urayama, S.; Zou, W.; Brooks, K.; Tolstikov, V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. *Rapid Commun. Mass Spectrom.* **2010**, *24*, 613–620.

50. Miyagi, Y.; Higashiyama, M.; Gochi, A.; Akaike, M.; Ishikawa, T.; Miura, T.; Saruki, N.; Bando, E.; Kimura, H.; Imamura, F.; et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. *PLoS One* **2011**, *6*, e24143.

51. Luo, Y.; Yoneda, J.; Ohmori, H.; Sasaki, T.; Shimbo, K.; Eto, S.; Kato, Y.; Miyano, H.; Kobayashi, T.; Sasahira, T.; et al. Cancer usurps skeletal muscle as an energy repository. *Cancer Res.* **2014**, *74*, 330–340.

52. Lob, S.; Konigsrainer, A.; Zieker, D.; Brucher, B.L.; Rammensee, H.G.; Opelz, G.; Terness, P. IDO1 and IDO2 are expressed in human tumors: Levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. *Cancer Immunol. Immunother.* **2009**, *58*, 153–157.

53. Lob, S.; Konigsrainer, A.; Rammensee, H.G.; Opelz, G.; Terness, P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: Can we see the wood for the trees? *Nat. Rev. Cancer* **2009**, *9*, 445–452.

54. Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. *Nat. Med.* **2005**, *11*, 312–319.
55. Zamanakou, M.; Germenis, A.E.; Karanikas, V. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. *Immunol. Lett.* **2007**, *111*, 69–75.

56. Warburg, O. On the origin of cancer cells. *Science* **1956**, *123*, 309–314.

57. Dunn, W.B.; Broadhurst, D.; Begley, P.; Zelena, E.; Francis-McIntyre, S.; Anderson, N.; Brown, M.; Knowles, J.D.; Halsall, A.; Haselden, J.N.; *et al.* Human serum metabolome (HUSERMET) consortium. procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nat. Protoc.* **2011**, *6*, 1060–1083.

58. Want, E.J.; Masson, P.; Michopoulos, F.; Wilson, I.D.; Theodoridis, G.; Plumb, R.S.; Shockcor, J.; Loftus, N.; Holmes, E.; Nicholson, J.K. Global metabolic profiling of animal and human tissues via UPLC-MS. *Nat. Protoc.* **2013**, *8*, 17–32.

59. Dunn, W.B.; Wilson, I.D.; Nicholls, A.W.; Broadhurst, D. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. *Bioanalysis* **2012**, *4*, 2249–2264.

60. Bijlsma, S.; Bobeldijk, I.; Verheij, E.R.; Ramaker, R.; Kochhar, S.; Macdonald, I.A.; van Ommen, B.; Smilde, A.K. Large-scale human metabolomics studies: A strategy for data (pre-) processing and validation. *Anal. Chem.* **2006**, *78*, 567–574.

61. Fiehn, O.; Wohlgemuth, G.; Scholz, M.; Kind, T.; Lee, D.Y.; Lu, Y.; Moon, S.; Nikolau, B. Quality control for plant metabolomics: Reporting MSI-compliant studies. *Plant J.* **2008**, *53*, 691–704.

62. Zou, W.; She, J.; Tolstikov, V.V. A comprehensive workflow of mass spectrometry-based untargeted metabolomics in cancer metabolic biomarker discovery using human plasma and urine. *Metabolites* **2013**, *3*, 787–819.

63. Broeckling, C.D.; Heuberger, A.L.; Prenni, J.E. Large scale non-targeted metabolomic profiling of serum by ultra performance liquid chromatography-mass spectrometry (UPLC-MS). *J. Vis. Exp.* **2013**, *73*, e50242.

64. Yu, Z.; Kastenmüller, G.; He, Y.; Beleredi, P.; Möller, G.; Prehn, C.; Mendes, J.; Wahl, S.; Roemisch-Margl, W.; Ceglarek, U.; *et al.* Differences between human plasma and serum metabolite profiles. *PLoS One* **2011**, *6*, e21230.

65. Yin, P.; Peter, A.; Franken, H.; Zhao, X.; Neukamm, S.S.; Rosenbaum, L.; Lucio, M.; Zell, A.; Häring, H.U.; Xu, G.; *et al.* Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. *Clin. Chem.* **2013**, *59*, 833–845.

66. Iob, V.; Mcmath, M.; Coon, W.W. Intra-individual and inter individual variations in plasma free amino acids in normal adults. *J. Surg. Res.* **1963**, *3*, 85–89.

67. Lavie, L.; Lavie, P. Daily rhythms in plasma levels of homocysteine. *J. Circadian Rhythm.* **2004**, *2*, doi:10.1186/1740-3391-2-5.

68. Zhang, A.; Sun, H.; Wang, P.; Han, Y.; Wang, X. Modern analytical techniques in metabolomics analysis. *Analyst* **2012**, *137*, 293–300.

69. Wang, X.; Yang, B.; Sun, H.; Zhang, A. Pattern recognition approaches and computational systems tools for ultra performance liquid chromatography-mass spectrometry-based comprehensive metabolomic profiling and pathways analysis of biological data sets. *Anal. Chem.* **2012**, *84*, 428–439.

70. Zhang, A.; Sun, H.; Wang, P.; Han, Y.; Wang, X. Recent and potential developments of biofluid analyses in metabolomics. *J. Proteomics* **2012**, *75*, 1079–1088.
71. Yeh, C.K.; Christodoulides, N.J.; Floriano, P.N.; Miller, C.S.; Ebersole, J.L.; Weigum, S.E.; McDevitt, J.; Redding, S.W. Current development of saliva/oral fluid-based diagnostics. *Tex. Dent. J.* 2010, 127, 651–661.
72. Giannobile, W.V.; McDevitt, J.T.; Niedbala, R.S.; Malamud, D. Translational and clinical applications of salivary diagnostics. *Adv. Dent. Res.* 2011, 23, 375–380.
73. Bigler, L.R.; Streckfus, C.F.; Dubinsky, W.P. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. *Clin. Lab. Med.* 2009, 29, 71–85.
74. Wong, D.T. Salivary diagnostics for oral cancer. *J. Calif. Dent. Assoc.* 2006, 34, 303–308.
75. Samaranayake, L. Saliva as a diagnostic fluid. *Int. Dent. J.* 2007, 57, 295–299.
76. Annesley, T.M. Ion suppression in mass spectrometry. *Clin. Chem.* 2003, 100, 6940–6945.
77. Lin, S.; Shaler, T.A.; Becker, C.H. Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. *Anal. Chem.* 2006, 78, 5762–5767.
78. Barnidge, D.; Goodmanson, M.; Klee, G.; Muddiman, D. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution MS. *J. Proteome Res.* 2004, 3, 644–652.
79. Arentsen, B.M.; Rijmen, L.; De Winter, A.; Smolinska, A.; Wouters, E.F.; van Schooten, F.J. The versatile use of exhaled volatile organic compounds in human health and disease. *J. Breath Res.* 2012, 6, 027108.
80. Kakuta, S.; Bando, Y.; Nishiumi, S.; Yoshida, M.; Fukusaki, E.; Bamba, T. Metabolic profiling of oxidized lipid-derived volatiles in blood by gas chromatography/mass spectrometry with in-tube extraction. *Mass Spectrom.* 2013, 2, A0018.
88. Römisch-Margl, W.; Prehn, C.; Bogumil, R.; Röhring, C.; Suhre, K.; Adamski, J. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. *Metabolomics* 2012, 8, 133–142.

89. Zukunft, S.; Sorgenfrei, M.; Prehn, C.; Ga, M.; Adamski, J. Targeted Metabolomics of Dried Blood Spot Extracts. *Chromatographia* 2013, 76, 1295–1305.

90. Lommen, A. MetAlign: Interface-driven, versatile metabolomics tool for hyphenated full-scan mass spectrometry data preprocessing. *Anal. Chem.* 2009, 81, 3079–3086.

91. Smith, C.A.; Want, E.J.; O’Maille, G.; Abagyan, R.; Siuzdak, G. XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Anal. Chem.* 2006, 78, 779–787.

92. Pluskal, T.; Castillo, S.; Villar-Briones, A.; Oresic, M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC Bioinform.* 2010, 11, doi:10.1186/1471-2105-11-395.

93. Tsugawa, H.; Tsujimoto, Y.; Arita, M.; Bamba, T.; Fukusaki, E. GC/MS based metabolomics: Development of a data mining system for metabolite identification by using soft independent modeling of class analogy (SIMCA). *BMC Bioinform.* 2011, 12, doi:10.1186/1471-2105-12-131.

94. Tsugawa, H.; Arita, M.; Kanazawa, M.; Ogiwara, A.; Bamba, T.; Fukusaki, E. MRMPROBS: A data assessment and metabolite identification tool for large-scale multiple reaction monitoring based widely targeted metabolomics. *Anal. Chem.* 2013, 85, 5191–5199.

95. Horai, H.; Arita, M.; Kanaya, S.; Nihei, Y.; Ikeda, T.; Suwa, K.; Ojima, Y.; Tanaka, K.; Tanaka, S.; Aoshima, K.; et al. MassBank: A public repository for sharing mass spectral data for life sciences. *J. Mass Spectrom.* 2010, 45, 703–714.

96. Wishart, D.S.; Jewison, T.; Guo, A.C.; Wilson, M.; Knox, C.; Liu, Y.; Djoumbou, Y.; Mandal, R.; Aziat, F.; Dong, E.; et al. HMDB 3.0-The Human Metabolome Database in 2013. *Nucl. Acids Res.* 2013, 41, D801–D807.

97. Kanehisa, M.; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucl. Acids Res.* 2000, 28, 27–30.

98. Thiele, I.; Swainston, N.; Fleming, R.M.; Hoppe, A.; Sahoo, S.; Aurich, M.K.; Haraldsdottir, H.; Mo, M.L.; Rolfsson, O.; Stobbe, M.D.; et al. A community-driven global reconstruction of human metabolism. *Nat. Biotechnol.* 2013, 31, 419–425.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).